PT - JOURNAL ARTICLE AU - Marcelo S. Conzentino AU - Tatielle P. C. Santos AU - Khaled A. Selim AU - Berenike Wagner AU - Janette T. Alford AU - Nelli Deobald AU - Nigela. M. Paula AU - Fabiane G. M. Rego AU - Dalila L. Zanette AU - Mateus N. Aoki AU - Jeanine M. Nardin AU - Maria C.C. Huergo AU - Rodrigo A. Reis AU - Luciano F. Huergo TI - Ultra-fast, high throughput and inexpensive detection of SARS-CoV-2 seroconversion AID - 10.1101/2021.04.13.21255396 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.13.21255396 4099 - http://medrxiv.org/content/early/2021/04/19/2021.04.13.21255396.short 4100 - http://medrxiv.org/content/early/2021/04/19/2021.04.13.21255396.full AB - A technique allowing high throughput, fast and low-cost quantitative analysis of human IgG antibodies reacting to SARS-CoV-2 antigens will be required to understand the levels of protecting antibodies in the population raised in response to infections and/or to immunization. We described previously a fast, simple, and inexpensive Ni2+ magnetic bead immunoassay which allowed detection of human antibodies reacting against the SARS-CoV-2 nucleocapsid protein using a minimal amount of serum or blood. A major drawback of the previously described system was that it only processed 12 samples simultaneously. Here we describe a manually operating inexpensive 96 well plate magnetic extraction / homogenization process which allows high throughput analysis delivering results of 96 samples in chromogenic format in 12 minutes or in fluorescent ultrafast format which takes only 7 minutes. We also show that His tag antigen purification can be performed on the fly while loading antigens to the Ni2+ magnetic beads in a process which takes only 12 min reducing the pre analytical time and cost. Finally, we show that the magnetic bead immunoassay is antigen flexible and can be performed using either Nucleocapsid, Spike or Spike RBD. The method performed with low inter and intra assay variability using different antigens and detection modes and was able to deliver >99.5% specificity and >95% sensitivity for a cohort of 203 pre pandemic and 63 COVID-19 positive samples.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Alexander von Humboldt foundation, UFPR, CNPq, CAPES and by the Fundacao Araucaria.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Review Board CEP/HEG (n# 31592620.4.1001.0098) and (179/2020/BO2, University Hospital Tubingen) approved this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFederal University of Parana UFPR has filed for patent protections for: the magnetic immunoassay process, magnetic COVID-19 immunological test product and magnetic bead extractor device and processing method. All designed product and processes will be freely available for academic and non-commercial users.